By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateEnrollment of Phase 2 Trial of AG013 to Complete in 4Q19Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAFREAD THE FULL MDNA.TO RESEARCH REPORTBusiness UpdateMedicenna Therapeutics Corp. (TSX:MDNA) (OTC:MDNAF) is a clinical stage immuno-oncology company developing novel versions of the cytokines Interleukin (IL)-2, IL-4, and IL-13, which they term ‘Superkines’. The Superkines can be utilized as monotherapies, used in combination with...
By Elizabeth Senko, CFAOTC:WIZPREAD THE FULL WIZP RESEARCH REPORT Wize Pharma, Inc. (OTC:WIZP) is a clinical-stage company focused on developing an in-licensed product, for the treatment of dry eye syndrome (DES) and related conditions including Sjögren’s syndrome and conjunctivochalasis (CCH). LO2A is approved and marketed by its inventor in several...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateMeeting with the FDA Regarding Exebacase Phase 3 PlanContraFect Corp. (NASDAQ:CFRX) is developing exebacase (CF-301) as the company’s lead lysin product. Lysins are naturally occurring anti-bacterial hydrolytic enzymes that are produced by bacteriophages, which are virus’ that infect and kill...
By David Bautz, PhDNASDAQ:DFFNREAD THE FULL DFFN RESEARCH REPORTBusiness UpdatePositive Safety Data for Dose Escalation Run-in of Phase 3 GBM TrialOn July 23, 2019, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the Data Safety Monitoring Board (DSMB) has unanimously recommended continuing the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT)...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTFinancial UpdateOn July 25, 2019, MediciNova, Inc. (NASDAQ:MNOV) filed form 10-Q with financial results for the second quarter of 2019. As expected, the company did not report any revenues for the second quarter of 2019. Net loss for the second quarter...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTFinancial UpdateOn August 8, 2019, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced financial results for the second quarter of 2019. The company recorded a total of $6.8 million in revenue for the three months ending June 30, 2019, which consisted of $6.1 million...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2b Trial for VK2809 to Initiate 2H19Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The...
By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORT Financial UpdateOn July 16, 2019, BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced that the previously announced rights offering was fully subscribed and the company raised gross proceeds of $20 million through the sale of 3,057,466 American Depository Shares (ADSs) and...
By John Vandermosten, CFANASDAQ:LPCN While there has been evidence of a relationship between low free testosterone (T) levels and non-alcoholic steatohepatitis (NASH) as well as between fibrosis and non-alcoholic fatty liver disease (NAFLD), until recently it had not yet been supported by a biopsy confirmed study in humans. The...